Journal of Hepato-Biliary-Pancreatic Sciences · 2022 · 12 citations · 19 references
MedicineOncologySurgeryGastrointestinal OncologyHepatologySurgical OncologyBiliary InterventionsBiliary Tract CancerBiliary Tract DiseaseHepatobiliary SurgeryLiver CancerStent PlacementBile Duct DiseaseBile Duct ObstructionBiliary Stent PlacementCovered Stent PlacementHilar Biliary ObstructionMalignant Biliary ObstructionMetallic Biliary StentsSuccess Rate Analysis
BACKGROUND: There have been few reports of covered self-expandable metallic stent (SEMS) placement for malignant hilar-biliary obstruction (MHBO) because of risk of biliary branch obstruction. We studied feasibility and efficacy of 6-mm-diameter, slim, fully covered SEMS (SFCSEMS) in a relatively large cohort. METHODS: We retrospectively evaluated SFCSEMS in unresectable MHBO from December 2016 to September 2021 in Juntendo University Hospital. RESULTS: We enrolled consecutive 54 unresectable MHBO (18 bile duct, 11 gallbladder, eight pancreatic, two hepatocellular, and 15 metastatic cancer cases) including Bismuth-type II (n = 11), III (n = 17), and IV (n = 26), and placed two (n = 35) or three (n = 19) SFCSEMS. The technical and clinical success rate was 100% and 92.5%, respectively, with 76.3 min of mean procedure time. Recurrent biliary obstruction (RBO) was observed in 35.2% and the median cumulative time to RBO (TRBO) was 181 days. Other adverse events were 11.1% (four mild-pancreatitis, one segmental-cholangitis, and one cholecystitis). There were no failed cases of stent exchange and second SFCSEMS (n = 6) showed significantly lower RBO (16.7% vs. 81.8%, P = .0364) and longer TRBO (undefined vs 86 days; P = .0617) than plastic stent (n = 11). CONCLUSIONS: Endoscopic placement of SFCSEMS for unresectable MHBO was effective and feasible with low incidence of segmental cholangitis, and exchange strategy of SFCSEMS was promising.
19
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Juan W. Valle, Harpreet Wasan, Daniel H. Palmer et al. · New England Journal of Medicine · 2010 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +12
ERCP-related adverse events: European Society of Gastrointestinal Endoscopy (ESGE) Guideline
Jean‐Marc Dumonceau, C Kapral, Lars Aabakken et al. · Endoscopy · 2019 · 874 citations · Full text
Medicine, Clinical Sciences, Surgery +17
Tae Hoon Lee, Tae Hyeon Kim, Jong Ho Moon et al. · Gastrointestinal Endoscopy · 2017 · 198 citations
Medicine, Surgery, Surgical Oncology +11